BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/15/2022 11:41:26 AM | Browse: 297 | Download: 705
 |
Received |
|
2022-07-20 06:46 |
|
Peer-Review Started |
|
2022-07-20 06:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-09-04 06:56 |
|
Revised |
|
2022-09-20 04:46 |
|
Second Decision |
|
2022-10-24 03:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-10-28 18:18 |
|
Articles in Press |
|
2022-10-28 18:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-10-20 22:38 |
|
Typeset the Manuscript |
|
2022-11-07 01:53 |
|
Publish the Manuscript Online |
|
2022-12-15 11:41 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Viswanathan Mohan, Subhash Wangnoo, Sambit Das, Rajnish Dhediya and Kumar Gaurav |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rajnish Dhediya, MBBS, MD, N/A, N/A, Medical Affairs, Dr. Reddy’s Laboratories Ltd, 7-1-27 Ameerpet, Hyderabad 500016, India. rajnishd@drreddys.com |
| Key Words |
Linagliptin; Gliclazide; Hypoglycemia; Major cardiovascular adverse events; Type 2 diabetes |
| Core Tip |
This systematic review showed the lack of high-quality evidence and head-to head trials comparing the cardiovascular safety and hypoglycemia risk of gliclazide (a sulfonylurea) vs linagliptin (dipeptidyl peptidase-4 inhibitor) in adults with type 2 diabetes and no cardiovascular disease. While dipeptidyl peptidase-4 inhibitors have been proven to be cardiovascular neutral, sulfonylureas like gliclazide are commonly prescribed and recommended glucose-lowering drugs in low resource settings. Hence, it is important to establish the cardiovascular safety and hypoglycemia risk of gliclazide vs linagliptin to highlight that gliclazide may be a cost-effective yet safe treatment option for patients with type 2 diabetes. |
| Publish Date |
2022-12-15 11:41 |
| Citation |
Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World J Diabetes 2022; 13(12): 1168-1183 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i12/1168.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i12.1168 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
